SRC:MixSentence, IDs:1F2180A7;38C5F1E7;24F2A662;D16FA106;24F0BE8E;176F41BE;0F354E03;DCA74BA0;AF24C528;1145CE81;A104E536;4F03F29E;FA6D331A;8340DF8F;1FADB78C;E504825E;F97F1B21;586FCD27;723A698E;4783AC6E;D70F9551;F7B5ECF5;102124F4;50E62F34;4001EF39;4CDE9612;8655D580;C0692D6E;A280F89D;8076E0A7;5327B9B5;F96696D0;BACBF0FD;8AA5A084;4B56E498;FCA73D64;33F4E1AB;C5FF299B;75B58E06;AD2F6436;44866C46;6F4F7993;6273BD03;4F886FA0;A2107323;99219F16;451E5718
Individual nurses using social media should remember there are still other sources for health information offline. Even if the total charge makes perfect sense given the work performed, it can still feel like a nasty shock if they weren’t braced for it. A top source of client frustration is the sense that a case is dragging on. Incorporating client feedback throughout the process can further build trust and ensure a positive experience. Clients often arrive at your office or log into a Zoom call carrying not just legal services troubles, but also worries, hopes, and misunderstandings about what the legal process can realistically do for them. Yes, clients appreciate quick responses. Court dockets, waiting periods, or slow-moving discovery can add weeks or months that clients didn’t see coming. Using a project management tool can further enhance client communication by organizing project workflows and facilitating regular status updates. Regular updates-whether they’re weekly, bi-weekly, or monthly, depending on the situation-also help clients see that you’re actively on top of their matter. Sending smaller, regular bills rather than one colossal invoice at the end can also help. Digital marketing can feel like a shot in the dark because there are so many platforms that you can use for content marketing.
SRC:MixSentence, IDs:DCA74BA0;A378FA11;8CDB195E;4AFB1C5A;DDF36E88;E39BB509;0E3D6250;75B58E06;3AD5669B;EEC85940;E6D040BB;9C9F8712;AF24C528;7748D293;F42FD8B5;3EFFCA51;42D3ECC2;3DA74DEE;8308B630;B5BEBCA6;59BFF157;F1FE3AF6;DC863CC7;6C181902;C6F0668D;00C312E8;0ECB4049;4001EF39;60570297;BCA08FF8;45378D1E;34295D83;029700BB;90C3508B;D70F9551;102124F4;B7B2D198;CEC0943E;BC393593;24F0BE8E;7366FF1E;8AA5A084;4F03F29E;AFA70CA3;CB8701E7
At Mail Shark, we are ready to work with you to not only develop a top-notch direct mail system but also to pinpoint exactly to whom you should be marketing your services through the U.S. From setup to go-live, we make sure your website reflects your brand perfectly and is ready to start driving new business from day one. Make your website uniquely yours with add-ons and tools that work the way you do and instantly earn client trust. Offer clients a quick way to estimate closing costs with a custom-branded net sheet calculator that collects prospect info and keeps them engaged while saving you time. So if you go to the Law Hawk videos that’s funny, but that’s generally attracting probably more again, I’m just saying this candidly, typically, more low value like clients and cases, typically younger demographic. Brochures are an attractive, convenient way for you to showcase your law firm’s history, services, and attorneys. Whether you’re a solo practitioner or a mid-sized law firm, you’ll appreciate having an attractive, expertly-created brochure that highlights the best benefits of working with you rather than a competitor. Law firm direct mail allows you to regularly send printed materials such as brochures, flyers, and postcards to the mailboxes of the people most likely to use or need your professional counsel.
nytimes.comSRC:MixSentence, IDs:1CB5D976;485FA936;3AD5669B;AF24C528;430C4AF5;DE757C7F;4F45A2FE;24F2A662;99219F16;FC8C0D50;63624C40;F78D37A9;1F46BF33;4F03F29E;C54A2492;1FADB78C;0ECB4049;04EFBA12;6B520626;E73F66B8;EA15627F;F3096291;39C9A45B;CEC0943E;C0692D6E;48263096;62457DA4
If this is where clinical research is headed, that would be a terrible negative trajectory," he said. Dr. Topol - who drew attention last year with a finding that Celebrex and its competitor, Vioxx, appeared to raise the risk of heart attacks - said the Bextra studies did not include enough patients to justify drawing a broad conclusion. The average age of patients in the study, 23, did not represent the population likely to take the drug, he added. Yet through publication in the leading dental journal, the research helped Bextra's marketers shift attention away from the F.D.A.'s negative findings. Because of confidentiality rules, the F.D.A. cannot release any information about the earlier pain studies that failed to sway regulators. "Even though the study lacked some important proof, the real problem is that in the dental literature, this will be read," Dr. Topol said. "And dentists, who have to deal with trying to prevent or modulate pain, will be impressed." Judy Glova, a spokeswoman for Pharmacia, said the drug company stood behind the design and conclusions of the Scirex studies. Pharmacia was not trying to bypass the regulatory process, she said, adding that the company is in discussions with regulators to have Bextra approved for acute pain. Scirex executives did not return repeated phone calls. Editors at The Journal of the American Dental Association said the Scirex article was reviewed by at least three scientists. One reviewer, Dr. Paul A. Moore, an associate editor of the journal, said the study was "carefully designed and rigorously performed." But Dr. Moore said he would have recommended that the journal reject the paper had he known that Bextra was not approved for acute pain. The Bextra episode is just one example of the changing face of drug research. In the early 1990's, about 75 percent of the drug industry's clinical research dollars went to universities, according to a study by CenterWatch, a company that tracks clinical trials. By 2000, just 34 percent went to academic institutions, while the rest went to investigators working under the direction of either a private research firm like Scirex or a pharmaceutical company. Omnicom says it has no control over Scirex. "We have nothing to do with the design of clinical studies," said Pat Sloan, an Omnicom spokeswoman. Yet when the ad agency paid $20 million for part-ownership of Scirex in 1999, a top Omnicom executive, Thomas L. Harrison, said he expected Scirex's research to produce positive results for drug company clients - results that would help speed new-drug applications, or N.D.A.'s, to the F.D.A. "Our goal," he said, "is to help guide ensure that all clinical studies and each patient accrued into a study can be assessed to support the N.D.A.holovaty.com